Edge Therapeutics

General Information

We are a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. Our initial product candidates target rare, acute, life-threatening neurological conditions for which we believe the approved existing therapies are inadequate.

Employees: 18
Founded: 2009
Contact Information
Address 200 Connell Drive, Suite 1600, Berkeley Heights, NJ 07922, US
Phone Number (800) 208-3343
Web Address http://www.edgetherapeutics.com
View Prospectus: Edge Therapeutics
Financial Information
Market Cap $302.5mil
Revenues $0.0 mil (last 12 months)
Net Income $-20.0 mil (last 12 months)
IPO Profile
Symbol EDGE
Exchange NASDAQ
Shares (millions): 7.3
Price range $11.00 - $11.00
Est. $ Volume $43.9 mil
Manager / Joint Managers Leerink Partners/ Credit Suisse
CO-Managers Guggenheim Securities/ JMP Securities
Expected To Trade: 10/1/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change